Lower-Limb Drainage Mapping in Pelvic Lymphadenectomy for Gynaecological Cancer

Overview

The purpose of this study is to evaluate the feasibility of an isotopic technique to identify, and to map the lower-limb drainage nodes during pelvic lymphadenectomy for gynaecological cancers. The diagnostic value of our mapping method will be assessed, and we will determine the incidence of lymhedema.

Full Title of Study: “Individualisation du Drainage Lymphatique Des Membres inférieurs Lors du Curage Pelvien Pour Cancer gynécologique”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 4, 2021

Detailed Description

Pelvic lymphadenectomy is associated with a significant risk of lower-limb lymphedema. In this study, we evaluate the feasibility of identifying the lower-limb drainage nodes (LLDNs) during pelvic lymphadenectomy for gynaecological cancers using an isotopic detection technique with a preoperative radiopharmaceutical injection into both feet Secondary objectives are to map lower-limb drainage, to assess the diagnostic value of our mapping technique, and to determine the incidence of lymphedema. LLDN mapping may allow the preservation of LLDNs, thereby decreasing the risk of lower-limb lymphedema and improving quality of life.

Interventions

  • Procedure: Lower-limb drainage isotopic intraoperative detection
    • A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.

Arms, Groups and Cohorts

  • Experimental: isotopic intraoperative detection
    • Lower-limb drainage isotopic intraoperative detection

Clinical Trial Outcome Measures

Primary Measures

  • Lower-limb drainage intraoperative isotopic detection rate in patients with pelvic lymphadenectomy for gynaecological cancers.
    • Time Frame: day of surgery

Secondary Measures

  • Anatomy of lower-limb drainage
    • Time Frame: day of surgery
  • Percentage of patients with metastatic lower limb sampling
    • Time Frame: 2 weeks after surgery
  • Follow-up of patients to identify complications, and namely lower-limb lymphedema.
    • Time Frame: 5 years

Participating in This Clinical Trial

Inclusion Criteria

  • Female patients 18 years of age or older with indication of pelvic lymphadenectomy for gynaecological malignancy: – High risk endometrial cancer (stage IB type I grade 3, stage I type II, stage> IB) or with metastatic sentinel lymph node, – Early cervical cancer, or with metastatic sentinel lymph node, – Ovarian cancer. – Must provide her signed and informed consent – Beneficiary of a health insurance – Having received a medical examination Exclusion Criteria:

  • Contraindication to pelvic lymphadenectomy – Presence of lymphedema of the lower limbs – Contraindication to radiomarkers (allergy or hypersensitivity to any component of the biomarker) – Patient with dementia or altered mental status – Pregnant or breast feeding patients – Participation in any other clinical trial that could interfere with the study results

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assistance Publique – Hôpitaux de Paris
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Anne-Sophie BATS, MD, PhD, Principal Investigator, assistance publique des hopitaux de paris

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.